MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, today announced completion of the sale of MacroGenics' good manufacturing practice (GMP) drug substance manufacturing operations to Bora.

GlobeNewsWire • Jul 2, 2026

MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?

Does MacroGenics (MGNX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Jul 2, 2026

MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval

ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the U.S. Food and Drug Administration's (FDA) accelerated approval of TZIELD® (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 type 1 diabetes (T1D). The approval expands the therapeutic potential of TZIELD as a disease-modifying therapy for type 1 diabetes.

GlobeNewsWire • Jun 22, 2026

MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum

ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum on Wednesday, May 20, 2026 at 10:30 a.m. ET.

GlobeNewsWire • May 14, 2026

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

ROCKVILLE, Md., May 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended March 31, 2026, and highlighted its recent corporate progress.

GlobeNewsWire • May 13, 2026

MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates

MacroGenics (MGNX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.65 per share a year ago.

Zacks Investment Research • May 13, 2026

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals

•MacroGenics to receive $122.5 million upfront payment from Bora upon closing•Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora

GlobeNewsWire • May 11, 2026

Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should Know

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • May 5, 2026

MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement

• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million • MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million

GlobeNewsWire • May 4, 2026

FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study

• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers   • On track to provide mid-2026 program update  ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the U. S. Food and Drug Administration (FDA) has removed the partial clinical hold on the Company's Phase 2 LINNET study of lorigerlimab, an investigational, bispecific DART® molecule that targets PD-1 and CTLA-4.

GlobeNewsWire • Apr 8, 2026